Skip to search formSkip to main contentSkip to account menu

Advate

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antihemophilic Factor, Human RecombinantFactor VIII
Antihemophilic Factor, Human Recombinant 1 UNT Injection [Advate]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation
Essentials Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in… 
2015
2015
The EPIC study: a lesson to learn
Inhibitory antibodies to factor VIII occur in about 30% of previously untreated patients (PUPs) and are the most serious… 
2015
2015
The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule
Prophylaxis prevents joint and other bleeding episodes in patients with haemophilia A. Development of new factor concentrates… 
2012
2012
A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate®)
Summary.  Haemostatic effect of compounds for treating haemophilia can be evaluated in various bleeding models in haemophilic… 
2011
2011
Bioequivalence between two serum‐free recombinant factor VIII preparations (N8 and ADVATE®) – an open‐label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
Summary.  Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for… 
2011
2011
Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,
Abstract 3323 Baxter is developing a PEGylated recombinant human factor VIII conjugate (BAX 855) based on the modification of… 
2007
2007
ReFacto® 1 and Advate® 2 : a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A
Summary.  ReFacto is a recombinant B‐domain‐deleted, monoclonal antibody‐purified, solvent‐detergent‐treated factor VIII… 
2006
2006
ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
By intention, there are similarities between ADVATE (ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (r… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)